Market capitalization | $1.44b |
Enterprise Value | $1.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 110.95 |
EV/Sales (TTM) EV/Sales | 3.21 |
P/S ratio (TTM) P/S ratio | 3.76 |
P/B ratio (TTM) P/B ratio | 3.30 |
Revenue growth (TTM) Revenue growth | 54.41% |
Revenue (TTM) Revenue | $384.10m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 384 384 |
54%
54%
|
|
Gross Profit | 234 234 |
40%
40%
|
|
EBITDA | -25 -25 |
65%
65%
|
EBIT (Operating Income) EBIT | -26 -26 |
36%
36%
|
Net Profit | -9.07 -9.07 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Head office | Bermuda |
CEO | Sanj Patel |
Employees | 297 |
Founded | 2015 |
Website | www.kiniksa.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.